

Special Issue

New Advances in the Pathology, Diagnosis and Treatment of Thyroid Tumors

Message from the Guest Editor

Thyroid cancer (TC) is a complex aspect of immunoncology and endocrinology, being associated with various biases and paradigms. In the clinic, the low incidence of Medullary TC is associated with the performance of fewer calcitonin tests than TSH, with thyroxin being used in initial screenings. Likewise, lymphomas are rarely recognized as a primary focus in the thyroid gland, because abundant lymphoid cells (including small lymphocytes from germinal centers) are observed in Hashimoto thyroiditis. Non-Hodgkin lymphoma is diagnosed via neck node biopsy, but this may have metastasized from the primary thyroid. Surgery is considered the optimum treatment; however, as in surgery, total thyroidectomy cannot be compared with subtotal, radioiodine or immunotherapy, especially when an observational strategy is employed. Finally, with a plateau in the incidence of thyroid cancer and an overestimation of local of TC (alongside the underreporting of metastatic of TC), the role of thyroid supplements remains unclear. Special Issue welcomes the submission of articles that focus on the mechanisms implicated in the oncogenesis of TC, its diagnosis and potential therapeutic regimens.

Guest Editor

Dr. Przemysław Zdziarski

PRION Private Research Institute of Nature, P.O. Box 1818, 50-385 Wrocław, Poland

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/234586

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).